Abstract
Topical vaginal microbicides to prevent HIV infection are urgently needed. Recent scientific progress has identified potential new molecular targets for microbicides, and six older candidates are starting phase III trials. However, regulatory hurdles to licensure risk delaying future availability in developing countries unless these obstacles are pro-actively addressed. Although clear safety and efficacy data for microbicides are essential, risk-benefit profiles differ enormously between developed countries, which by default dominate global regulatory decisions, and developing regions where microbicides are needed most. This Policy Forum suggests actions to avoid regulatory logjams in making safe and efficacious microbicides available to women in resource-poor, HIV-prevalent settings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
